Associated Retina Consultants

Running trials

• Recruiting

  A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

  NCT07029945· Phase 1/2· Source

• Recruiting

  A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions

  NCT07734064· Phase 1· Source

• Recruiting

  Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD

  NCT07770828· Phase 3· Source

• Recruiting

  Study of ALK-001 on the Progression of Stargardt Disease

  NCT07419334· Phase 3· Source

• Recruiting

  A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

  NCT07425574· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

  NCT06659445· Phase 2· Source

• Recruiting

  A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

  NCT07161544· Phase 1/2· Source

• Active, not recruiting

  Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

  NCT06912633· Phase 2· Source

• Recruiting

  A Study of AMDX-2011P in Participants With Alzheimer's Disease

  NCT06514001· Phase 2· Source

• Recruiting

  A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

  NCT06556368· Phase 3· Source

• Recruiting

  A Study of AMDX-2011P in Participants With CAA

  NCT05709314· Phase 2· Source

• Active, not recruiting

  A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

  NCT06388200· Phase 3· Source

• Active, not recruiting

  ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

  NCT06373731· Phase 3· Source

• Active, not recruiting

  Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

  NCT06018558· Phase 1/2· Source

• Active, not recruiting

  A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

  NCT05956626· Phase 2/3· Source

• Active, not recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)

  NCT06847854· Phase 1· Source

• Active, not recruiting

  Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis

  NCT05203939· Phase 1/2· Source

• Active, not recruiting

  A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

  NCT04108156· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration5 recruiting
• Alzheimer disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)

  NCT06172257· Phase 3· Source

• Completed

  Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

  NCT05891548· Phase 2· Source

• Completed

  QA102 Phase II Study in Subjects With Dry AMD

  NCT05536752· Phase 2· Source

• Completed

  Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)

  NCT05447650· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Source

• Completed

  Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

  NCT04567303· Phase 1/2· Source

• Completed

  A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

  NCT04503551· Phase 3· Source

• Recruiting

  Extension Study for the Port Delivery System With Ranibizumab (Portal)

  NCT03683251· Phase 3· Source